Methods and compositions for treating viral or virally-induced conditions
Provided are methods and compositions for the prevention and/or treatment of viral conditions, virally-induced conditions and inflammatory conditions. The methods can comprise administering to a subject a viral inducing agent with an antiviral agent, and optionally an additional agent. The viral inducing agent can be a HDAC inhibitor administered orally.
1. A method for treating a virally-induced condition comprising administering an HDAC inhibitor, wherein the HDAC inhibitor comprises CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide), and wherein the virally-induced condition is multiple sclerosis.
2. A method for treating and/or preventing an inflammatory condition comprising administering:
a. a histone deacetylase inhibitor (HDAC inhibitor), wherein the HDAC inhibitor comprises CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide); and
b. an antiviral agent,
wherein the inflammatory condition is an autoimmune condition, and wherein the autoimmune condition is multiple sclerosis.
3. The method of claim 2 , wherein the antiviral agent comprises valganciclovir.
4. The method of claim 2 , wherein the antiviral agent is acyclovir, ganciclovir, valganciclovir, or famciclovir.